Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics, Inc. (Nasdaq: VERA) is a late clinical-stage biotechnology company committed to developing and commercializing pioneering treatments for patients with serious immunological diseases. The company's primary product candidate, atacicept, is a fusion protein designed for subcutaneous injection once weekly. Atacicept blocks both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), thereby inhibiting the stimulation of B cells and plasma cells that produce autoantibodies contributing to autoimmune diseases such as IgA nephropathy (IgAN) and lupus nephritis.
One of the company's significant achievements is the development of atacicept, which has shown promising results in clinical trials. The Phase 2b ORIGIN clinical trial demonstrated atacicept's potential to modify disease progression in IgAN patients, with data showing consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, along with stable eGFR over 72 weeks. The ongoing pivotal Phase 3 ORIGIN 3 trial aims to further evaluate atacicept's efficacy and safety in a larger cohort of IgAN patients.
Additionally, Vera is advancing MAU868, a monoclonal antibody designed to neutralize BK virus (BKV) infections, which are particularly problematic in kidney transplant patients. Vera retains global developmental and commercial rights to both atacicept and MAU868, positioning the company well in the biopharmaceutical market.
Financially, Vera reported a net loss of $28.4 million for the quarter ended March 31, 2024, with sufficient cash reserves to fund operations through the potential approval and U.S. launch of atacicept. The company has also announced various strategic partnerships and funding rounds to support its ambitious research and development goals.
Recently, Vera Therapeutics received FDA Breakthrough Therapy Designation for atacicept in IgAN, indicating the drug's potential to substantially improve kidney function compared to existing therapies. This designation expedites the development and review process, bringing hope to patients suffering from this debilitating disease.
For more information about Vera Therapeutics and its clinical trials, please visit the company's website at www.veratx.com.
Vera Therapeutics (Nasdaq: VERA), a late clinical-stage biotechnology company specializing in immunological disease treatments, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston, MA from March 3-5, 2025.
The company's management team will engage in a fireside chat scheduled for Tuesday, March 4, 2025, at 9:10 AM EST. Additionally, they will conduct one-on-one investor meetings during the conference.
The fireside chat will be accessible via webcast, with a replay available for 90 days through the Investor Calendar section of Vera Therapeutics' website.
Vera Therapeutics (NASDAQ: VERA) provided its Q4 and full year 2024 business update, highlighting progress in its atacicept development program for IgA Nephropathy (IgAN). The company is on track to announce primary endpoint results from the pivotal Phase 3 ORIGIN trial in Q2 2025, with BLA submission planned for H2 2025.
Key developments include receiving FDA Breakthrough Therapy Designation for atacicept in IgAN and presenting positive 96-week eGFR stabilization data. Vera expanded atacicept's development pipeline to include multiple autoimmune kidney diseases and acquired rights to VT-109, a next-generation fusion protein.
Financial highlights show a net loss of $152.1 million ($2.75 per share) for 2024, compared to $96.0 million ($2.25 per share) in 2023. The company reported $640.9 million in cash and equivalents, strengthened by approximately $593.2 million in net proceeds from two equity financings in 2024.
Vera Therapeutics (NASDAQ: VERA) announced inducement awards granted by its Compensation Committee on February 8, 2025, to seventeen new employees. The awards include non-qualified stock options to purchase 157,750 shares of Class A common stock and restricted stock units (RSUs) for 78,875 shares.
The stock options have an exercise price of $36.14 per share, based on Vera's closing price on February 7, 2025. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest over four years, with 25% vesting annually starting February 20, 2025. Both awards require continued employment with Vera and are subject to the Inducement Plan terms.
Vera Therapeutics (NASDAQ: VERA) announced the granting of inducement awards to six new employees on January 8, 2025. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), include:
- Non-qualified stock options to purchase 35,250 shares of Class A common stock at $42.19 per share (Vera's closing price on January 8, 2025)
- Restricted stock units (RSUs) for 17,625 shares of Class A common stock
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 25% vesting annually starting February 20, 2025. Both awards require continued employment with Vera and are subject to the Inducement Plan terms and conditions.
Vera Therapeutics (Nasdaq: VERA) has secured an exclusive license agreement with Stanford University for VT-109, a novel next-generation fusion protein targeting BAFF and APRIL. The technology has broad therapeutic potential across B cell mediated diseases. The agreement grants Vera development and marketing rights in exchange for undisclosed upfront and milestone payments.
According to CEO Marshall Fordyce, this acquisition aligns with Vera's lifecycle management strategy to strengthen its position in B cell modulation. The company plans to utilize its expertise in research, translational medicine, clinical development, and commercialization to advance the molecule's potential.
Vera Therapeutics (Nasdaq: VERA), a late clinical-stage biotechnology company specializing in immunological disease treatments, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, scheduled for January 12-16, 2025.
The company's management team will deliver a presentation on Monday, January 13, 2025, at 4:30 PM PST. The presentation will be accessible via webcast, and investors can view it through the J.P. Morgan meetings platform. Additionally, the management team will engage in one-on-one meetings with investors during the conference.
A replay of the presentation will remain available for 90 days through the 'Investor Calendar' section of Vera Therapeutics' website.
Vera Therapeutics (NASDAQ: VERA) announced inducement grants approved by its Compensation Committee on December 3, 2024. The grants, awarded to seventeen new employees, include non-qualified stock options to purchase 171,750 shares of Class A common stock at $49.38 per share and restricted stock units (RSUs) for 86,625 shares.
The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly over 36 months. The RSUs will vest over four years, with 25% vesting annually starting February 20, 2025. Both grants are subject to continued employment with Vera and were made under the Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted to Jason S. Carter, their new Chief Legal Officer, on November 18, 2024. The awards include a non-qualified stock option to purchase 108,000 shares of Class A common stock at $44.81 per share and restricted stock units (RSUs) for 53,000 shares. The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest 25% annually over four years starting November 20, 2024, subject to continued employment.
Vera Therapeutics (NASDAQ: VERA) has appointed Jason S. Carter as Chief Legal Officer, effective immediately. Carter brings over 20 years of legal experience, most recently serving as Global Head of Legal for Kite Pharma. The appointment comes as Vera prepares for its pivotal ORIGIN 3 trial of atacicept in IgAN, with topline results expected in Q2 2025 and planned BLA submission to FDA later that year. Carter's experience includes overseeing legal activities in global product launches, R&D, manufacturing, IP litigation, and M&A transactions at companies including Daiichi Sankyo, Novartis, and Baxter.
Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted to seven new employees on November 4, 2024. The awards include non-qualified stock options to purchase 54,050 shares of Class A common stock at $45.17 per share and restricted stock units (RSUs) for 27,025 shares. The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest 25% annually over four years starting November 20, 2024. These grants were approved under Nasdaq Listing Rule 5635(c)(4) as employment inducements.
FAQ
What is the current stock price of Vera Therapeutics (VERA)?
What is the market cap of Vera Therapeutics (VERA)?
What is Vera Therapeutics?
What is atacicept?
What is the ORIGIN clinical trial?
What is IgA nephropathy (IgAN)?
What is MAU868?
What recent achievements has Vera Therapeutics reported?
How is atacicept administered?
What are the financial highlights of Vera Therapeutics?
Who are Vera’s strategic partners?
Where can I find more information about Vera Therapeutics?
